Liquid AbobotulinumtoxinA: Pooled Data From Two Double-Blind, Randomized, Placebo-Controlled Phase III Studies of Glabellar Line Treatment

Said Hilton, Philippe Kestemont, Gerhard Sattler, Magali Volteau, Catherine Thompson, Bill Andriopoulos, Inna Prygova, Anna-Karin Berg, Benjamin Ascher, Said Hilton, Philippe Kestemont, Gerhard Sattler, Magali Volteau, Catherine Thompson, Bill Andriopoulos, Inna Prygova, Anna-Karin Berg, Benjamin Ascher

Abstract

Background: AbobotulinumtoxinA (aboBoNT-A) solution is a new ready-to-use formulation developed to reduce preparation time and improve reproducibility of injections.

Objective: To further evaluate treatment of moderate-to-severe glabellar lines (GLs) using pooled data from 2 Phase III studies.

Methods: Following double-blind treatment with 50 U aboBoNT-A solution (n = 251) or placebo (n = 123), GL severity was assessed by investigators (ILA) and subjects (SSA). Other assessments included subject-reported time to onset, subject satisfaction, FACE-Q, and adverse events.

Results: One month after aboBoNT-A solution treatment, 88% had none-or-mild GLs at maximum frown and 93% had ≥1-grade improvement in ILA (similar for SSA), 24% to 27% remaining improved at Month 6. Glabellar lines responder rates remained higher than placebo throughout Month 6 ( p < .001). Almost two-thirds of subjects reported onset within 3 days, nearly a quarter reporting effect by Day 1. Subject satisfaction with GL appearance, and FACE-Q satisfaction with facial appearance overall and psychological well-being were also improved over placebo throughout Month 6, p < .05. Treatment-related adverse events were nonserious and mild or moderate.

Conclusion: Pooled analysis confirmed a duration of effect on GLs of up to 6 months for aboBoNT-A solution, with onset starting within 24 hours, high subject satisfaction, and improved psychological well-being. The treatment was well tolerated.

Trial registration: ClinicalTrials.gov NCT02353871 NCT02493946.

Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society for Dermatologic Surgery, Inc.

Figures

Figure 1.
Figure 1.
None-or-mild glabellar line severity responders at maximum frown (mITT population); a responder had improved from moderate (Grade 2) or severe (Grade 3) at baseline to none (Grade 0) or mild (Grade 1) post-treatment. Error bars show 95% confidence intervals. For ILA and SSA, the difference between aboBoNT-A solution and placebo was statistically significant at all time points, p < .0001 up to Month 5 and p < .001 at Month 6.
Figure 2.
Figure 2.
≥1-grade improvement from baseline in glabellar line severity at maximum frown (mITT population). Error bars show 95% confidence intervals. For ILA and SSA, the difference between aboBoNT-A solution and placebo was statistically significant at all time points, p < .0001.
Figure 3.
Figure 3.
Subject satisfaction responder rates over time (mITT population). Responders were “satisfied” or “very satisfied” with the appearance of their glabellar lines post-baseline and “dissatisfied” or “very dissatisfied” at baseline. Error bars show 95% confidence intervals. The difference between aboBoNT-A solution and placebo was statistically significant at all time points, p < .0001.

References

    1. Monheit GD, Baumann L, Maas C, Rand R, et al. . Efficacy, safety, and subject satisfaction after AbobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatol Surg 2020;46:61–9.
    1. Cohen JL, Scuderi N. Safety and patient satisfaction of AbobotulinumtoxinA for aesthetic use: a systematic review. Aesthet Surg J 2017;37:S32–S44.
    1. Rzany B, Ascher B, Monheit G. Treatment of glabellar lines with botulinum toxin type A (Speywood Unit): a clinical overview. J Eur Acad Dermatol Venereol 2010;24(Suppl 1):1–14.
    1. Schlessinger J, Cohen JL, Shamban A, Jacob C, et al. . A multicenter study to evaluate subject satisfaction with two treatments of AbobotulinumtoxinA a year in the glabellar lines. Dermatol Surg 2021;47:504–9.
    1. Ascher B, Kestemont P, Boineau D, Bodokh I, et al. . Liquid formulation of AbobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthet Surg J 2018;38:183–91.
    1. Ascher B, Rzany B, Kestemont P, Hilton S, et al. . Liquid formulation of AbobotulinumtoxinA: a 6-month, Phase 3, double-blind, randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines. Aesthet Surg J 2020;40:93–104.
    1. Kestemont P, Hilton S, Andriopoulos B, Prygova I, et al. . Long-term efficacy and safety of liquid AbobotulinumtoxinA formulation for moderate-to-severe glabellar lines: a Phase III, double-blind, randomized, placebo-controlled and open-label study. Aesthet Surg J 2022;42:301–13.
    1. Honeck P, Weiss C, Sterry W, Rzany B, et al. . Reproducibility of a four-point clinical severity score for glabellar frown lines. Br J Dermatol 2003;149:306–10.
    1. Pusic AL, Klassen AF, Scott AM, Cano SJ. Development and psychometric evaluation of the FACE-Q satisfaction with appearance scale: a new patient-reported outcome instrument for facial aesthetics patients. Clin Plast Surg 2013;40:249–60.
    1. Klassen AF, Cano SJ, Schwitzer JA, Scott AM, et al. . FACE-Q scales for health-related quality of life, early life impact, satisfaction with outcomes, and decision to have treatment: development and validation. Plast Reconstr Surg 2015;135:375–86.
    1. Joseph J, Moradi A, Lorenc ZP, Coleman K, et al. . AbobotulinumtoxinA for the treatment of moderate-to-severe glabellar lines: a randomized, dose-escalating, double-blind study. J Drugs Dermatol 2021;20:980–7.
    1. Brandt F, Swanson N, Baumann L, Huber B. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatol Surg 2009;35:1893–901.
    1. Moy R, Maas C, Monheit G, Huber MB, et al. . Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg 2009;11:77–83.
    1. Gubanova E, Haddad Tabet M, Bergerova Y, Moiseieva O, et al. . Assessment of subject and physician satisfaction after long-term treatment of glabellar lines with AbobotulinumtoxinA (Dysport((R))/Azzalure((R))): primary results of the APPEAL noninterventional study. Aesthet Plast Surg 2018;42:1672–80.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren